Kontafarma China Holdings Limited (HKG:1312)
Hong Kong
· Delayed Price · Currency is HKD 0.0280
0.00 (0.00%)
At close: Mar 10, 2026
Kontafarma China Holdings Revenue
Kontafarma China Holdings had revenue of 452.72M HKD in the half year ending June 30, 2025, with 5.11% growth. This brings the company's revenue in the last twelve months to 891.73M, up 6.55% year-over-year. In the year 2024, Kontafarma China Holdings had annual revenue of 897.52M with 10.93% growth.
Revenue (ttm)
891.73M
Revenue Growth
+6.55%
P/S Ratio
0.18
Revenue / Employee
1.36M
Employees
655
Market Cap
156.48M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 897.52M | 88.41M | 10.93% |
| Dec 31, 2023 | 809.11M | -84.96M | -9.50% |
| Dec 31, 2022 | 894.06M | 90.80M | 11.30% |
| Dec 31, 2021 | 803.27M | -205.87M | -20.40% |
| Dec 31, 2020 | 1.01B | 87.99M | 9.55% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| PuraPharm Corporation | 346.76M |
| Joyzyme Group | 28.24M |
| Extrawell Pharmaceutical Holdings | 52.65M |
| Tianda Pharmaceuticals | 310.50M |
| Shenzhen Neptunus Interlong Bio-technique Company | 1.09B |
| Regent Pacific Group | 6.54M |
| Wai Yuen Tong Medicine Holdings | 721.27M |
| Sanai Health Industry Group Company | 104.88M |